Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Spyre Therapeutics, Inc. (SYRE) had Weighted-Average Shares Outstanding (Diluted) of 60.27M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-44.77M |
|
-- |
|
-- |
|
$53.57M |
|
$-53.57M |
|
$8.78M |
|
$-44.79M |
|
$-44.79M |
|
$-44.77M |
|
$-44.77M |
|
$-44.77M |
|
$-44.77M |
|
$-53.57M |
|
$-53.57M |
|
60.27M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
60.27M |
$-0.60 |
|
$-0.60 |
|
| Balance Sheet Financials | |
$569.77M |
|
-- |
|
$0.01M |
|
$569.78M |
|
$70.68M |
|
-- |
|
$16.49M |
|
$87.17M |
|
$326.79M |
|
$482.61M |
|
$482.61M |
|
60.28M |
|
| Cash Flow Statement Financials | |
$-40.99M |
|
$-0.06M |
|
$0.12M |
|
$89.42M |
|
$48.49M |
|
$-40.93M |
|
$8.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-40.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.70% |
|
-9.28% |
|
-7.86% |
|
-9.28% |
|
$8.01 |
|
$-0.68 |
|
$-0.68 |
|